View Filing Data

Product Revenues [Member] | Customer Two [Member]

50.00%

Summary Of Significant Accounting Policies [Line Items]

Product Revenues [Member] | Customer Three [Member]

32.00%

Summary Of Significant Accounting Policies [Line Items]

Accounts Receivable | Customer One [Member]

18.00%

Summary Of Significant Accounting Policies [Line Items]

Accounts Receivable | Customer Two [Member]

66.00%

Summary Of Significant Accounting Policies [Line Items]

Accounts Receivable | Customer Three [Member]

21.00%

Summary Of Significant Accounting Policies [Line Items]

Summary Of Significant Accounting Policies [Line Items]

13.00%

Minimum [Member]

Accounts receivable payment term

30 days

Maximum [Member]

Summary Of Significant Accounting Policies [Line Items]

Accounts receivable payment term

60 days

[1]

Litigation Settlement and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jul. 31, 2017	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fee to be paid on execution of agreements	$ 35,000,000
Intangible asset		$ 14,029,000	$ 14,029,000	$ 8,076,000
Settlement and license charges		25,588,000	28,427,000
U.S. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Intangible asset		6,600,000	6,600,000
BioMarin Pharmaceuticals, Inc. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Up-front cash payment under agreements	$ 35,000,000		35,000,000
Amortization of intangible assets and royalties license agreement execution expenses		$ 800,000	$ 2,300,000
BioMarin Pharmaceuticals, Inc. [Member] \| U.S. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payment expiry period	2023-12
BioMarin Pharmaceuticals, Inc. [Member] \| EU [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payment expiry period	2024-09
Settlement Agreement [Member] \| BioMarin Pharmaceuticals, Inc. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fee to be paid on execution of agreements	$ 20,000,000
License Agreement [Member] \| BioMarin and Academisch Ziekenhuis Leiden [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fee to be paid on execution of agreements	15,000,000
Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory and sales milestone payments	$ 65,000,000
Percentage of royalty payments	8.00%
Minimum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of royalty payments	4.00%

Gain From Sale of Priority Review Voucher - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2017
Gain From Sale Of Intangible Asset [Line Items]
Gain from sale of PRV asset		$ 125,000
Gilead [Member]
Gain From Sale Of Intangible Asset [Line Items]
Gain from sale of PRV asset	$ 125,000

Assets Measured and Carried at Fair Value (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 558,700	$ 207,915
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	360,612	1,147
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	83,506	69,304
Government and Government Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	113,934	105,287
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		20,834
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	648	11,343
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	361,260	12,490
Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	360,612	1,147
Level 1 [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	648	11,343
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	197,440	195,425
Level 2 [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	83,506	69,304
Level 2 [Member] \| Government and Government Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 113,934	105,287
Level 2 [Member] \| Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		$ 20,834

Cash, Cash Equivalents and Short-Term Investments - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2017
Cash And Cash Equivalents [Abstract]
Weighted average maturity period of available-for-sale securities	4 months
Available-for-sale securities	$ 317,845,000	$ 0

Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	$ 617,642,000
Cash and cash equivalents, Gross unrealized gains	1,000
Cash and cash equivalents, Gross unrealized losses	(13,000)
Cash and cash equivalents, Fair market value	617,630,000
Cash, cash equivalents and short-term investments, Amortized cost		$ 317,965,000
Cash, cash equivalents and short-term investments, Gross unrealized losses		(120,000)
Cash, cash equivalents and short-term investments, Fair market value	0	317,845,000
Cash and Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	420,190,000
Cash and cash equivalents, Fair market value	420,190,000
Cash, cash equivalents and short-term investments, Amortized cost		122,420,000
Cash, cash equivalents and short-term investments, Fair market value		122,420,000
Commercial Paper [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	83,516,000
Cash and cash equivalents, Gross unrealized losses	(10,000)
Cash and cash equivalents, Fair market value	83,506,000
Cash, cash equivalents and short-term investments, Amortized cost		69,355,000
Cash, cash equivalents and short-term investments, Gross unrealized losses		(51,000)
Cash, cash equivalents and short-term investments, Fair market value		69,304,000
Government and Government Agency Bonds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	113,936,000
Cash and cash equivalents, Gross unrealized gains	1,000
Cash and cash equivalents, Gross unrealized losses	(3,000)
Cash and cash equivalents, Fair market value	113,934,000
Cash, cash equivalents and short-term investments, Amortized cost		105,340,000
Cash, cash equivalents and short-term investments, Gross unrealized losses		(53,000)
Cash, cash equivalents and short-term investments, Fair market value		105,287,000
Cash and Cash Equivalents [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	617,642,000
Cash and cash equivalents, Gross unrealized gains	1,000
Cash and cash equivalents, Gross unrealized losses	(13,000)
Cash and cash equivalents, Fair market value	$ 617,630,000
Cash, cash equivalents and short-term investments, Amortized cost		122,420,000
Cash, cash equivalents and short-term investments, Fair market value		122,420,000
Corporate Bonds [Member]
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost		20,850,000
Cash, cash equivalents and short-term investments, Gross unrealized losses		(16,000)
Cash, cash equivalents and short-term investments, Fair market value		20,834,000
Short-term Investments [Member]
Cash and Cash Equivalents [Line Items]
Cash, cash equivalents and short-term investments, Amortized cost		195,545,000
Cash, cash equivalents and short-term investments, Gross unrealized losses		(120,000)
Cash, cash equivalents and short-term investments, Fair market value		$ 195,425,000

Accounts Receivable and Reserves for Product Sales - Summary of Components of Accounts Receivable (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Receivables Net Current [Abstract]
Product sales, net of reserves	$ 23,822	$ 4,002
Government contract receivables	929	1,226
Total accounts receivable	$ 24,751	$ 5,228

Accounts Receivable and Reserves for Product Sales - Summary of Change in Reserves for Discounts and Allowances (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2017 USD ($)
Accounts Notes And Loans Receivable [Line Items]
Balance, as of December 31, 2016	$ 306
Provision	8,880
Payments/credits	(4,634)
Balance, as of September 30, 2017	4,552
Chargebacks [Member]
Accounts Notes And Loans Receivable [Line Items]
Balance, as of December 31, 2016	1
Provision	3,760
Payments/credits	(3,330)
Balance, as of September 30, 2017	431
Rebates [Member]
Accounts Notes And Loans Receivable [Line Items]
Balance, as of December 31, 2016	238
Provision	4,270
Payments/credits	(660)
Balance, as of September 30, 2017	3,848
Prompt Pay [Member]
Accounts Notes And Loans Receivable [Line Items]
Provision	78
Payments/credits	(52)
Balance, as of September 30, 2017	26
Other Accruals [Member]
Accounts Notes And Loans Receivable [Line Items]
Balance, as of December 31, 2016	67
Provision	772
Payments/credits	(592)
Balance, as of September 30, 2017	$ 247

Accounts Receivable and Reserves for Product Sales - Summary of Total Reserves Included in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Receivables Net Current [Abstract]
Reduction to accounts receivable	$ 457	$ 1
Component of accrued expenses	4,095	305
Total reserves	$ 4,552	$ 306

Inventory - Summary of Components of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 44,257	$ 9,531
Work in progress	20,144	3,175
Finished goods	292	107
Total inventory	$ 64,693	$ 12,813

Asset Held for Sale - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Aug. 31, 2017	Sep. 30, 2017	Sep. 30, 2017	Mar. 31, 2017
Asset Held For Sale Current [Abstract]
Net book value of airport facility reclassified as an assets held for sale, current		$ 1,501	$ 1,501	$ 1,500
Sale price of airport facility	$ 1,500
Fees related to sale of airport facility	$ 200
Loss from anticipated sale of assets		$ 200	$ 200

Summary of Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Manufacturing-related deposits and prepaids	$ 18,399	$ 23,604
Prepaid clinical and preclinical expenses	3,612	1,225
Other prepaids	4,000	1,152
Other	1,022	914
Total other current assets	$ 27,033	$ 26,895

Summary of Other Non-current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Noncurrent [Abstract]
Prepaid clinical expenses	$ 7,056	$ 3,725
Manufacturing-related deposits	3,570
Other	362	242
Total other non-current assets	$ 10,988	$ 3,967

Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Accrued contract manufacturing costs	$ 13,438	$ 4,673
Accrued clinical and preclinical costs	13,123	10,033
Accrued employee compensation costs	10,560	8,748
Accrued professional fees	5,520	2,799
Product revenue related reserves	4,095	305
Accrued income taxes	3,493
Accrued BioMarin royalties	2,289
Accrued research costs	317	1,186
Other	2,917	3,272
Total accrued expenses	$ 55,752	$ 31,016

Indebtedness - Additional Information (Detail)

1 Months Ended

3 Months Ended

9 Months Ended

Jul. 31, 2017

USD ($)

Sep. 30, 2017

USD ($)

Loan

Sep. 30, 2017

USD ($)

Loan

Sep. 30, 2016

USD ($)

Dec. 31, 2016

USD ($)

Repayment of outstanding balance

$ 15,081,000

$ 5,076,000

Net proceeds from issuance of debt

29,620,000

Number of loans outstanding | Loan

$ 37,741,000

Total indebtedness of unpaid principal balance

$ 1,300,000

Interest expense related to outstanding loans

800,000

1,200,000

Revolving Loan [Member]

July 2017 Term Loan [Member]

^[1]

1,026,000

Net proceeds from issuance of debt

29,100,000

Long-term debt

30,000,000

Debt issuance costs

1,100,000

June 2015 Term Loan [Member]

Repayment of outstanding balance

9,200,000

Long-term debt

$ 15,000,000

Loan One [Member]

800,000

Loan Two [Member]

MidCap Financial Amended and Restated Credit and Security Agreement [Member] | July 2017 Term Loan [Member]

$ 500,000

Current borrowing capacity

$ 60,000,000

Credit agreement interest rate per annum

6.25%

Variable interest rate description

one-month London Interbank Offered Rate

Origination fee, percentage

0.50%

Final payment fee, percentage

2.00%

Monthly principal payments commencement date

Jul. 01, 2018

Periodic principal payment frequency

monthly

Monthly principal payments

$ 800,000

Credit facility maturity date

2021-07

Debt instrument prepayment fee percent within twelve months

3.00%

Debt instrument prepayment fee percent on or after twelve months and within twenty four months

2.00%

Debt instrument prepayment fee percent on or after twenty four months

1.00%

Percentage of minimum amount of cash and/or cash equivalents on outstanding principal amounts

75.00%

Midcap Financial Revolving Credit and Security Agreement [Member] | Revolving Loan [Member]

Current borrowing capacity

$ 40,000,000

Credit agreement interest rate per annum

3.95%

Variable interest rate description

one-month LIBOR

Origination fee, percentage

0.50%

Credit facility maturity date

2021-07

Percentage of minimum amount of cash and/or cash equivalents on outstanding principal amounts

75.00%

Line of credit facility additional tranche that may be increased

$ 20,000,000

Origination fee

$ 200,000

Mortgage Loans [Member]

Credit agreement interest rate per annum

4.75%

Credit facility maturity date

2027-02

^[1]

$ 1,307,000

[1]	Includes interest

Indebtedness - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Other loans	$ 2,319	$ 1,373
Total long-term debt	31,282	16,150
2017 Term Loan [Member]
Debt Instrument [Line Items]
Principal amount of term loan	30,000
2015 Term Loan [Member]
Debt Instrument [Line Items]
Principal amount of term loan		15,000
Term Loan [Member]
Debt Instrument [Line Items]
Unamortized debt issuance expense	(1,037)	(223)
Total long-term debt	$ 28,963	$ 14,777

Indebtedness - Summarizes Total Payments under Company's Debt Arrangements (Detail)
$ in Thousands

Sep. 30, 2017

USD ($)

$ 2,906

6,389

11,611

10,855

5,980

37,741

2017

573

^[1]

2018

6,389

^[1]

2019

11,611

^[1]

2020

10,855

^[1]

2021

5,980

^[1]

Total Payments

35,408

^[1]

Mortgage Loans [Member]

2017

1,307

^[1]

Total Payments

1,307

^[1]

Revolver [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

2017

1,026

^[1]

Total Payments

$ 1,026

^[1]

[1]	Includes interest

Equity Offerings - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended			9 Months Ended
	Jul. 31, 2017	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2017
Class Of Stock [Line Items]
Common stock issued		5.8	2.1
Common stock average price per share	$ 42.50	$ 59.75	$ 17.84
Net proceeds from issue of common stock		$ 327.4	$ 37.3	$ 354.0
Underwriting discounts, commission and offering expenses		$ 17.6	$ 0.2	$ 20.0
Underwriting discount and commission per share			$ 1.60
Underwritten Public Offering [Member]
Class Of Stock [Line Items]
Common stock issued	8.8
Underwritten Offering [Member]
Class Of Stock [Line Items]
Common stock issued	1.2

Restructuring - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 30, 2017	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			$ 13	$ 1,264	$ 2,773	$ 2,423
Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring expenses					$ 2,400
Workforce Reduction [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring expenses				$ 1,000		$ 2,100
Corvallis Plan [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring, initiation date					2016-03
Restructuring, completion date					Sep. 30, 2017
Minimum lease payment obligation					$ 5,200
Corvallis Plan [Member] \| Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 2,300	$ 1,500

Summary of Restructuring Expenses by Function (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost And Reserve [Line Items]
Total restructuring expenses, Cash	$ 13	$ 995	$ 2,773	$ 1,919
Total restructuring expenses, Non-cash		269		504
Total restructuring expenses	13	1,264	2,773	2,423
Research and Development [Member]
Restructuring Cost And Reserve [Line Items]
Total restructuring expenses, Cash	10	628	184	1,448
Total restructuring expenses, Non-cash		143		336
Total restructuring expenses	10	771	184	1,784
Selling, General and Administrative [Member]
Restructuring Cost And Reserve [Line Items]
Total restructuring expenses, Cash	3	367	2,589	471
Total restructuring expenses, Non-cash		126		168
Total restructuring expenses	$ 3	$ 493	$ 2,589	$ 639

Summary of Restructuring Reserve (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Restructuring And Related Activities [Abstract]
Restructuring reserve beginning balance	$ 1,588
Restructuring expenses incurred during the period	2,773	$ 3,651
Amounts paid during the period	(1,318)	(2,063)
Restructuring reserve ending balance	$ 3,043	$ 1,588

Summary of Stock Awards Granted (Detail) - $ / shares

3 Months Ended

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Stock Options [Member]

Grants, Stock options

221,398

1,050

4,678,357

^[1]

1,214,426

Weighted Average Grant Date Fair Value, Stock options

$ 21.07

$ 37.38

$ 14.49

$ 11.96

Restricted Stock Units [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grants, Restricted stock units and awards

^[2]

181,029

Weighted Average Grant Date Fair Value, Restricted stock units and awards

$ 33.03

Restricted Stock Awards (RSAs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grants, Restricted stock units and awards

91,778

341,500

^[3]

117,553

Weighted Average Grant Date Fair Value, Restricted stock units and awards

$ 48.94

$ 34.58

$ 41.22

[1]	In June 2017, the Company granted its new CEO 3,300,000 options with service and market conditions. These options have a five-year cliff vesting schedule. The fair value of $13.48 for these options was determined by a lattice model with Monte Carlo simulations. The remaining 1,378,357 service-based options which have a weighted average grant date fair value of $16.90 have a four-year vesting schedule with 25% vesting on the first anniversary and 1/48 monthly thereafter.
[2]	The Company granted executives 156,029 restricted stock units (“RSUs”) with certain sales target and regulatory milestones. In June 2017, one performance condition of these RSUs was achieved. As a result, 50% of these RSUs became immediately vested and, accordingly, the Company recorded $2.5 million of stock-based compensation expenses. As of September 30, 2017, it is probable that the second performance milestone will be achieved within the required timeline. Accordingly, the Company recognized approximately $0.3 million of stock-based compensation expenses. The third performance milestone was deemed as not probable of being achieved as of September 30, 2017. If and when deemed probable that the last performance milestone may be achieved within the required time frame, the Company may recognize up to $1.1 million of stock-based compensation related to the second and third performance milestones of these grants. The remaining RSUs are service-based awards granted to the members of the board of directors.
[3]	In June 2017, the Company granted its new CEO 335,000 restricted stock awards (“RSAs”) with a fair value of $34.65. These RSAs have a four-year vesting schedule with 25% vesting on the first anniversary and 1/48 vest monthly thereafter.

Summary of Stock Awards Granted (Parenthetical) (Detail) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

Jun. 30, 2017

Sep. 30, 2017

Jun. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expenses

$ 6,922,000

$ 9,573,000

$ 23,099,000

$ 23,093,000

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options granted

221,398

1,050

4,678,357

^[1]

1,214,426

Fair value of options granted

$ 21.07

$ 37.38

$ 14.49

$ 11.96

Stock-based compensation expenses

$ 5,420,000

$ 8,778,000

$ 17,221,000

$ 20,248,000

Service-Based Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options granted

1,378,357

Fair value of options granted

$ 16.90

Restricted Stock Awards (RSAs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted average fair value of stock units granted

91,778

341,500

^[2]

117,553

$ 48.94

$ 34.58

$ 41.22

Restricted Stock Units [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted average fair value of stock units granted

^[3]

181,029

$ 33.03

Vest Monthly Thereafter [Member] | Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vest Monthly Thereafter [Member] | Restricted Stock Awards (RSAs) [Member]

0.02%

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

CEO [Member] | Stock Options [Member]

0.02%

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options granted

3,300,000

Cliff vesting schedule

5 years

Fair value of options granted

$ 13.48

Vesting period

4 years

CEO [Member] | Restricted Stock Awards (RSAs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

4 years

Weighted average fair value of stock units granted

335,000

$ 34.65

CEO [Member] | Vest First Anniversary [Member] | Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

CEO [Member] | Vest First Anniversary [Member] | Restricted Stock Awards (RSAs) [Member]

25.00%

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Executives [Member] | Restricted Stock Units [Member]

25.00%

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expenses

156,029

$ 2,500,000

$ 300,000

Executives [Member] | Restricted Stock Units [Member] | Performance Grants Vested Immediately [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]